Key Insights

Highlights

Success Rate

81% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

8.8%

3 terminated out of 34 trials

Success Rate

81.3%

-5.3% vs benchmark

Late-Stage Pipeline

6%

2 trials in Phase 3/4

Results Transparency

0%

0 of 13 completed with results

Key Signals

81% success

Data Visualizations

Phase Distribution

22Total
Not Applicable (18)
P 2 (2)
P 4 (2)

Trial Status

Completed13
Unknown10
Not Yet Recruiting5
Terminated3
Withdrawn2
Recruiting1

Trial Success Rate

81.3%

Benchmark: 86.5%

Based on 13 completed trials

Clinical Trials (34)

Showing 20 of 20 trials
NCT06340269Not ApplicableCompletedPrimary

Feasibility Pilot Study to Evaluate the Safety and Performance of the MEX-CD1 Medical Device in ACLF

NCT05124041Not ApplicableCompletedPrimary

Goal-Directed Hemostatic Resuscitation Trial in ACLF Induced Coagulopathy

NCT07422948Not ApplicableNot Yet RecruitingPrimary

Efficacy and Safety of Early Initiation of Midodrine for Control and Prevention of Ascites and Its Related Complications in Acute-on-chronic Liver Failure.

NCT05146336Recruiting

CytOSorb TreatMent Of Critically Ill PatientS Registry

NCT05059795Completed

Volume Resuscitation in Cirrhosis With Sepsis Induced Hypotension

NCT06815770Phase 2Not Yet RecruitingPrimary

Efficacy and Safety of Continuous Infusion of Terlipressin vs Bolus Terlipressin in ACLF Patients With Acute Esophageal Variceal Bleed

NCT06808009Not ApplicableNot Yet RecruitingPrimary

Goal Directed Ammonia Lowering Therapy in Hyperammonemic ACLF Patients With no Overt HE to Reduce Major Adverse Liver Related Outcomes (GOAL Trial)

NCT06556472Not ApplicableNot Yet RecruitingPrimary

Safety and Efficacy of Continuous Infusion of Terlipressin With Norepinephrine Versus Norepinephrine Alone in Improving Outcomes of Acute Kidney Injury in Acute on Chronic Liver Failure With Septic Shock

NCT05772585Withdrawn

Characterization of Metabolomic Fingerprints in Patients With Acute Liver Failure and Acute-on-chronic Liver Failure With Hepatic Encephalopathy

NCT03343756Terminated

HepaStem Long-Term Safety Registry

NCT04229901Phase 2TerminatedPrimary

Study to Evaluate the Efficacy and Safety of HepaStem in Patients With Acute on Chronic Liver Failure (ACLF)

NCT06276907Not ApplicableNot Yet RecruitingPrimary

An Open-label Randomized Controlled Trial Comparing the Role of Therapeutic Plasma-exchange in Ameliorating Secondary Organ Dysfunctions in Patients With ACLF and Develop Biomarkers of Treatment Response

NCT06116305UnknownPrimary

Lactate Kinetics as a Predictor of Survival in ACLF With Septic Shock

NCT06069284UnknownPrimary

Prognostic Significance of Acute Change in Liver and Splenic Stiffness in Patients of Acute on Chronic Liver Failure

NCT06066814UnknownPrimary

To Study the Role of Plasma Von Willebrand Factor Antigen (vWF) to A Disintegrin-like and Metalloproteinase With Thrombospondin Type-1 Motifs 13 (ADAMTS-13) Activity Ratio as a Predictor of Development of Extrahepatic Organ Failure in Acute on Chronic Liver Failure (ACLF) Patients.

NCT05672589Not ApplicableUnknown

To Compare Relaxed Rotational Thromboelastometry Cut-offs With Standard Cut-offs for Guiding Blood Product Use Before Invasive Procedures in Cirrhosis and Acute on Chronic Liver Failure Patients

NCT05131230WithdrawnPrimary

CytoSorb® in Patients With Acute on Chronic Liver Failure

NCT03577938Not ApplicableCompletedPrimary

Study on the Optimal Strategy for Acute-on-chronic Liver Failure With Integrative Treatment

NCT05180292Not ApplicableUnknownPrimary

Acute Hemodynamic Response to Carvedilol in Predicting Survival in Acute on Chronic Liver Failure Patients - A Pilot Study.

NCT03065699Not ApplicableCompletedPrimary

Safety and Performance Trial of DIALIVE Liver Dialysis Device in Acute On Chronic Liver Failure Patients

Scroll to load more

Research Network

Activity Timeline